I-131偏氧苄基胍治疗嗜铬细胞瘤和副神经节瘤是一个重要的治疗选择。

IF 1 4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuklearmedizin-nuclear Medicine Pub Date : 2022-06-01 DOI:10.1055/a-1759-2050

Xue Zhang, H. Wakabayashi, Daiki Kayano, A. Inaki, S. Kinuya

{"title":"I-131偏氧苄基胍治疗嗜铬细胞瘤和副神经节瘤是一个重要的治疗选择。","authors":"Xue Zhang, H. Wakabayashi, Daiki Kayano, A. Inaki, S. Kinuya","doi":"10.1055/a-1759-2050","DOIUrl":null,"url":null,"abstract":"AIM\nPheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours of chromaffin cells. Several modalities are currently available to treat patients with PPGL. These treatment modalities include surgery, chemotherapy, molecular targeted therapy and radiopharmaceuticals.\n\n\nMETHODS\nI-131 metaiodobenzylguanidine (mIBG), a classic radiopharmaceutical, can be taken up through specific receptors and sited into many, but not all, PPGL cells.\n\n\nRESULTS\nMany studies have investigated the efficacy and toxicity of I-131 mIBG therapy. These studies reported significant results in terms of objective, hormonal and symptomatic responses as well as tolerable toxicities in patients.\n\n\nCONCLUSION\nThis article reviews the reported experiences of patients who underwent I-131 mIBG therapy for PPGL with a focus on functions and deficiencies of the therapy.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"1 1","pages":"231-239"},"PeriodicalIF":1.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma.\",\"authors\":\"Xue Zhang, H. Wakabayashi, Daiki Kayano, A. Inaki, S. Kinuya\",\"doi\":\"10.1055/a-1759-2050\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"AIM\\nPheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours of chromaffin cells. Several modalities are currently available to treat patients with PPGL. These treatment modalities include surgery, chemotherapy, molecular targeted therapy and radiopharmaceuticals.\\n\\n\\nMETHODS\\nI-131 metaiodobenzylguanidine (mIBG), a classic radiopharmaceutical, can be taken up through specific receptors and sited into many, but not all, PPGL cells.\\n\\n\\nRESULTS\\nMany studies have investigated the efficacy and toxicity of I-131 mIBG therapy. These studies reported significant results in terms of objective, hormonal and symptomatic responses as well as tolerable toxicities in patients.\\n\\n\\nCONCLUSION\\nThis article reviews the reported experiences of patients who underwent I-131 mIBG therapy for PPGL with a focus on functions and deficiencies of the therapy.\",\"PeriodicalId\":19238,\"journal\":{\"name\":\"Nuklearmedizin-nuclear Medicine\",\"volume\":\"1 1\",\"pages\":\"231-239\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuklearmedizin-nuclear Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-1759-2050\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuklearmedizin-nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-1759-2050","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

嗜铬细胞瘤和副神经节瘤是罕见的嗜铬细胞神经内分泌肿瘤。目前有几种治疗PPGL的方法。这些治疗方式包括手术、化疗、分子靶向治疗和放射性药物。方法si -131 metaiodobenzylguanidine (mIBG)是一种经典的放射性药物，可以通过特定受体被吸收，并进入许多(但不是全部)PPGL细胞。结果许多研究调查了I-131 mIBG治疗的疗效和毒性。这些研究在客观、激素和症状反应以及患者可耐受的毒性方面报告了显著的结果。本文综述了I-131 mIBG治疗PPGL患者的经验，重点介绍了该治疗的功能和不足。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma.

AIM Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours of chromaffin cells. Several modalities are currently available to treat patients with PPGL. These treatment modalities include surgery, chemotherapy, molecular targeted therapy and radiopharmaceuticals. METHODS I-131 metaiodobenzylguanidine (mIBG), a classic radiopharmaceutical, can be taken up through specific receptors and sited into many, but not all, PPGL cells. RESULTS Many studies have investigated the efficacy and toxicity of I-131 mIBG therapy. These studies reported significant results in terms of objective, hormonal and symptomatic responses as well as tolerable toxicities in patients. CONCLUSION This article reviews the reported experiences of patients who underwent I-131 mIBG therapy for PPGL with a focus on functions and deficiencies of the therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nuklearmedizin-nuclear Medicine 医学-核医学

CiteScore

1.70

自引率

13.30%

发文量

267

审稿时长

>12 weeks

期刊介绍： Als Standes- und Fachorgan (Organ von Deutscher Gesellschaft für Nuklearmedizin (DGN), Österreichischer Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (ÖGN), Schweizerischer Gesellschaft für Nuklearmedizin (SGNM, SSNM)) von hohem wissenschaftlichen Anspruch befasst sich die CME-zertifizierte Nuklearmedizin/ NuclearMedicine mit Diagnostik und Therapie in der Nuklearmedizin und dem Strahlenschutz: Originalien, Übersichtsarbeiten, Referate und Kongressberichte stellen aktuelle Themen der Diagnose und Therapie dar. Ausführliche Berichte aus den DGN-Arbeitskreisen, Nachrichten aus Forschung und Industrie sowie Beschreibungen innovativer technischer Geräte, Einrichtungen und Systeme runden das Konzept ab. Die Abstracts der Jahrestagungen dreier europäischer Fachgesellschaften sind Bestandteil der Kongressausgaben. Nuklearmedizin erscheint regelmäßig mit sechs Ausgaben pro Jahr und richtet sich vor allem an Nuklearmediziner, Radiologen, Strahlentherapeuten, Medizinphysiker und Radiopharmazeuten.